C
Cygnus Biosciences
A Chinese gene sequencing company
About Cygnus Biosciences
Cygnus Bio is a biotechnology company specializing in advanced DNA sequencing technologies. The company serves a diverse range of clients, including research institutions, healthcare providers, and pharmaceutical companies. Operating in the rapidly growing genomics market, Cygnus Bio's core product, the Cygnus S100 DNA sequencer, is designed to deliver accurate, fast, flexible, and economical sequencing solutions. The business model is centered around the sale of its proprietary sequencing hardware and consumables, as well as offering sequencing services. Revenue is generated through direct sales, service contracts, and partnerships with key industry players. Cygnus Bio aims to revolutionize the genomics field by making high-quality DNA sequencing accessible and affordable for a broad spectrum of applications.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 18
- Open positions
- 5
- Dealroom signal
- 27.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Genetics and genomics, Health Diagnostics, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jul 2025 | — | — | Shunxi Private Equity Fund Management | ↗ |
| SERIES COther financing | Mar 2023 | $28M | $110M | Founder Hesheng Investment · Source Code Capital · CCB Private Equity Investment Management · Yuhuan State Investment | ↗ |
Growth signals
Latest recorded traffic for Cygnus Biosciences is 50 monthly website visits, down 92.5% over the last three months. Cygnus Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cygnus Biosciences in the Changping District ecosystem
The Cygnus Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Proxima Ventures
Zhongguancun Development Group- SIShanghai Creation Investment
- GCGeneral Technology Venture Capital
Series B and later9 investors entered at this stage
- THTechnology Holdings
China Structural Reform Fund- GSGuolian Securities
- FIFounder Hesheng Investment
Source Code Capital- CMCCB Private Equity Investment Management
- YIYuhuan State Investment
- HCHetang Venture Capital
- SMShunxi Private Equity Fund Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cygnus Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cygnus Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








